|Manufacturer:||Bristol-Myers Squibb Medical Imaging|
Distributed byBristol-Myers Squibb Medical Imaging331 Treble Cove RoadN.Billerica, Massachusetts 01862 USA For Ordering Tel: Toll Free 800-225-1572All Other Business: 800-362-2668(For Massachusetts and International, call 978-667-9531)Printed in the U.S.A.513121-0503May 2003
Myocardial Imaging: CARDIOLITE®, Kit for the Preparation of Technetium Tc99m Sestamibi for Injection, is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions.CARDIOLITE® evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling).It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia.Breast Imaging: MIRALUMA®, Kit for the Preparation of Technetium Tc99m Sestamibi for Injection, is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass.MIRALUMA® is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy.
In studying patients in whom cardiac disease is known or suspected, care should be taken to assure continuous monitoring and treatment in accordance with safe, accepted clinical procedure.
Infrequently, death has occurred 4 to 24 hours after Tc99m Sestamibi use and is usually associated with exercise stress testing (See Precautions).Pharmacologic induction of cardiovascular stress may be associated with serious adverse events such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction and cerebrovascular events.
Caution should be used when pharmacologic stress is selected as an alternative to exercise; it should be used when indicated and in accordance with the pharmacologic stress agent's labeling.Technetium Tc99m Sestamibi has been rarely associated with acute severe allergic and anaphylactic events of angioedema and generalized urticaria.
In some patients the allergic symptoms developed on the second injection during CARDIOLITE® imaging.
Patients who receive CARDIOLITE® or MIRALUMA® imaging are receiving the same drug.
Caution should be exercised and emergency equipment should be available when administering Technetium Tc99m Sestamibi.Also, before administering either CARDIOLITE® or MIRALUMA®, patients should be asked about the possibility of allergic reactions to either drug.